超微量肿瘤液体活检

Ultra-high sensitivity ctDNA liquid biopsy

HaploX CUBE-ctDNA sequencing technology can accurately identify trace quantities of circulating tumor DNA in the blood, with sensitivity as low as 0.05%!

超微量肿瘤液体活检

The Second Largest Gene Sequencing Center in the world

HaploX has the world's most advanced platforms: Illumina's NextSeq, HiSeq X Ten, NovaSeq 6000 serial sequencing and digital PCR, with sequencing throughput capability ranking second in the world, and tumor gene data output ranking first in China.


超微量肿瘤液体活检

Professional Team

HaploX was formed by a group of young, talented scientists specializing in genomics, bioinformatics, molecular biology, medicine, machine learning, big data mining and other related areas.

Technological Superiority

技术优势

5 Core Technologies

CUBE-ctDNA Sequencing Technology

Precision Capture of Circulating Tumor DNA

Excellent Bioinformatics Team

Advanced Machine Learning and Big Data Analyses

Single Molecule Coding Processing and Analysis

Learn More

News

HaploX has closed a several hundred millions Series B financing round.

June 28, 2018, HaploX announced the completion of several hundred million B round financing. the industry leader—Shenzhen Capital Group Co., Ltd. assisted HaploX in researching cancer precision medicine.<read more>

HaploX @ ASCO 2018, Voiced at the International Conference on Oncology [03]

HaploX CTO Shifu Chen revealed that sample store time might affect the result of TMB test.<read more>

HaploX @ ASCO 2018, Voiced at the International Conference on Oncology [02]

HaploX combined Shenzhen People's Hospital team to explore early detection of colorectal cancer.<read more>

HaploX @ ASCO 2018, Voice at the International Conference on Oncology [01]

HaploX joined the team of the School of Medicine from New Mexico University and the Shenzhen People's Hospital in advance to point out the signs of tumor recurrence.<read more>

The good news of Haplab— passed CAP competence verification with perfect score.

June 2018, HaploX Laboratory was given ten out of ten for CAP competence verification once again.<read more>

HapLab passed the external quality test conducted by EMQN.

Nov 14, 2017. HapLab passed the external quality test project Lung Cancer (NSCLC) conducted for EMQN excellently.<read more>